XLO

Xilio Therapeutics, Inc.

Tremor tracks 4 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

XLOXilio Development, Inc.
0Calm
XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors
Signing up patientsPhase 1/2180 patientsMain results: Nov 2029
XLOXilio Development, Inc.
0Calm
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
FinishedPhase 1/2125 patientsMain results: May 18, 2026
XLOXilio Development, Inc.
0Calm
XTX301 in Patients With Advanced Solid Tumors
Signing up patientsPhase 1/2358 patientsMain results: Sep 2028
XLOXilio Development, Inc.
0Calm
XTX202 in Patients With Advanced Solid Tumors
FinishedPhase 1/295 patientsMain results: Mar 22, 2025

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 0 purchases

No insider sales or purchases in the last 6 months.

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.